For instance, co-administration of PD-1 inhibitors with glycolytic inhibitors such as 2-deoxy-D-glucose (2-DG) has been shown to restore CD8+ T cell function and reduce tumor burden in murine models of head and HNSCC, including LSCC. The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.